Miracle Mile Advisors LLC Has $1.50 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Miracle Mile Advisors LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 68.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,366 shares of the biopharmaceutical company's stock after purchasing an additional 962 shares during the quarter. Miracle Mile Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $1,501,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. Apollon Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 8.2% in the fourth quarter. Apollon Wealth Management LLC now owns 1,722 shares of the biopharmaceutical company's stock valued at $1,227,000 after acquiring an additional 130 shares in the last quarter. Kingsview Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 16.5% in the fourth quarter. Kingsview Wealth Management LLC now owns 1,002 shares of the biopharmaceutical company's stock valued at $714,000 after acquiring an additional 142 shares in the last quarter. Empowered Funds LLC increased its stake in shares of Regeneron Pharmaceuticals by 687.5% during the fourth quarter. Empowered Funds LLC now owns 13,010 shares of the biopharmaceutical company's stock valued at $9,267,000 after acquiring an additional 11,358 shares during the period. Finally, Kestra Private Wealth Services LLC increased its stake in shares of Regeneron Pharmaceuticals by 12.9% during the fourth quarter. Kestra Private Wealth Services LLC now owns 1,926 shares of the biopharmaceutical company's stock valued at $1,372,000 after acquiring an additional 220 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ REGN traded down $4.93 during mid-day trading on Wednesday, reaching $518.60. The company had a trading volume of 961,902 shares, compared to its average volume of 873,023. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $55.99 billion, a price-to-earnings ratio of 13.55, a PEG ratio of 2.34 and a beta of 0.31. The stock has a fifty day moving average of $565.85 and a two-hundred day moving average of $654.03. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the company earned $9.55 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on REGN. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday. Royal Bank of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a report on Friday, May 30th. Citigroup decreased their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $700.00 to $580.00 in a research report on Friday, May 30th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.